SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001000694-23-000011
Filing Date
2023-04-04
Accepted
2023-04-04 16:34:03
Documents
13
Period of Report
2023-03-30
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K nvax-20230330.htm   iXBRL 8-K 36943
2 EX-3.1 novavaxinc-amendedandresta.htm EX-3.1 125297
  Complete submission text file 0001000694-23-000011.txt   313190

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT nvax-20230330.xsd EX-101.SCH 1912
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT nvax-20230330_lab.xml EX-101.LAB 24833
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT nvax-20230330_pre.xml EX-101.PRE 13053
7 EXTRACTED XBRL INSTANCE DOCUMENT nvax-20230330_htm.xml XML 4259
Mailing Address 21 FIRSTFIELD ROAD GAITHERSBURG MD 20878
Business Address 21 FIRSTFIELD ROAD GAITHERSBURG MD 20878 240-268-2000
NOVAVAX INC (Filer) CIK: 0001000694 (see all company filings)

IRS No.: 222816046 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-26770 | Film No.: 23798358
SIC: 2836 Biological Products, (No Diagnostic Substances)